Cerebrolysin

CognitivePeptide hydrolysate / nootropic researchExperimental

Also known as: FPE 1070, Porcine brain hydrolysate

Cerebrolysin (also called FPE 1070 or Porcine brain hydrolysate) is a peptide hydrolysate in the Neurotrophic peptide complex class. Mixture of low-molecular-weight neuropeptides claimed to mimic neurotrophic-factor activity (BDNF/GDNF-like effects) and support neuronal survival after ischemia in clinical and preclinical literature.

Calculate Dose

For research use only.

Key Facts

CAS
12656-49-6
Molecular Weight (MW)
Mixture of low-MW peptides
Half-life
Mixture; component PK not a single value
FDA status
Not Approved
Evidence level
Clinical Trial Evidence
Human dose established
Yes
Administration Route
Intravenous infusion (the route in the large trials)
Frequency
Once daily
Last updated
Nov 7, 2026
Reviewed
Nov 7, 2026
Targets
Neuronal survival pathwaysNeurotrophic signaling

Vendor price snapshot

Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected in Nov 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.

Vendors listing this peptide
10
Listed offers
14
Median price per mg
$1.15/mg
Typical $1.13–$1.54/mg

Open calculator · Compare vendors

Research summary

Peptide hydrolysate prepared from porcine brain tissue, supplied as a mixture of low-molecular-weight peptides and free amino acids rather than a single characterised compound. It is used in several countries in Europe and Asia for stroke, traumatic brain injury and dementia, where it is given by injection. Not FDA-approved in the United States, and because it is a mixture its composition is not standardised the way a single-entity drug would be.

Research evidence

  • Regulatory review (FDA label)None in reviewed sources
  • Controlled human trials2 reviewed sources
  • Early or uncontrolled human studiesNone in reviewed sources
  • Lab & animal studiesNone in reviewed sources
How it works

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

Peptide Library's Cerebrolysin profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.

Cerebrolysin dosage evidence

Cerebrolysin has no approved dosage in the United States. In the large stroke trials it was dosed by volume: 30 mL once daily by intravenous infusion for 10 days in the CASTA trial (n=1,070), and 30 mL once daily for 21 days alongside rehabilitation in the CARS trial. CASTA did not meet its primary endpoint; CARS reported better arm function at day 90.

Clinical Trial Evidence
Dosage evidence summary for Cerebrolysin
Human dosing establishedYes
RouteIntravenous infusion (the route in the large trials)
FrequencyOnce daily
Duration studied10–21 days in the stroke trials
Evidence levelClinical Trial Evidence
Last reviewed2026-11-07

Research-reported dosing

Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.

Research-reported dosing for Cerebrolysin, one row per studied regimen
Study / contextPopulationDoseRouteFrequencyDurationOutcome studiedSource
CASTA — acute ischaemic stroke in Asia (2012)Clinical trial · Double-blind randomised placebo-controlled trialAdults with acute ischaemic hemispheric stroke, treated within 12 hours of onset (n=1,070)30 mL a day, with aspirin 100 mg a dayIntravenous infusionOnce daily10 daysNo significant difference on the combined primary endpoint (modified Rankin Scale, Barthel Index, NIHSS)Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke. 2012.
CARS — recovery after stroke (2016)Clinical trial · Double-blind randomised placebo-controlled multicentre trialAdults in early rehabilitation after stroke, treated from 24–72 hours after onset30 mL a dayNot stated in the indexed abstractOnce daily21 daysAction Research Arm Test score at day 90 favoured cerebrolysin; the authors called the study exploratoryCerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke. 2016.

Where sources disagree

  • Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids prepared from pig brain, not a single peptide, so it is dosed in millilitres rather than milligrams.
  • This profile's general route lists intramuscular use, but the large stroke trials gave 30 mL by intravenous infusion. Trial volumes do not transfer to intramuscular injection.
  • Results are mixed: the largest trial, CASTA, missed its primary endpoint, while the smaller CARS trial reported a benefit and asked for confirmation in a large trial.
Cerebrolysin dosage in published studies and labels →

Handling & administration

Injection Sites
Abdomen
Timing Notes
Administer as a standalone; avoid mixing to preserve balance.

Sequence & molecular data

Sequence and molecular data for Cerebrolysin
Molecular weightMixture of low-MW peptides
CAS number12656-49-6
Half-lifeMixture; component PK not a single value
AppearanceIntramuscular injection (solution)
FormulationSolution

Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.

Science

Mechanism of Action

Mixture of low-molecular-weight neuropeptides claimed to mimic neurotrophic-factor activity (BDNF/GDNF-like effects) and support neuronal survival after ischemia in clinical and preclinical literature.

Origin

Enzymatic hydrolysate of porcine brain proteins.

Targets

Neuronal survival pathwaysNeurotrophic signaling

Research statistics

591 PubMed publications · 37.5% human clinical research · 40 registered trials

Counts of published research through 2026-11-15, not evidence that it works. Publications by year, study types and trials · How publications are counted

Regulatory & research status

Cerebrolysin is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

Regulatory and research status for Cerebrolysin
FDA statusNot Approved
AvailabilityResearch-Only
WADA (sport)Unknown / Not Listed
Library classificationResearch-Only

How FDA approval, compounding and research-only status differ

Benefits

Stroke/dementia research literatureNeurotrophic mixture

Cerebrolysin side effects

The effects below are those reported in Cerebrolysin clinical trials; long-term safety data may still be limited.

Side Effects

  • Injection reactions
  • Agitation
  • Headache
  • Rare hypersensitivity

Storage & stability

This compound is not supplied as a powder to be mixed, so the freeze-dried powder and reconstitution handling described for research peptides does not apply. Storage conditions are product-specific: follow the label or packaging of the product itself.

Cerebrolysin: frequently asked questions

What is Cerebrolysin?

Peptide hydrolysate prepared from porcine brain tissue, supplied as a mixture of low-molecular-weight peptides and free amino acids rather than a single characterised compound. It is used in several countries in Europe and Asia for stroke, traumatic brain injury and dementia, where it is given by injection. Not FDA-approved in the United States, and because it is a mixture its composition is not standardised the way a single-entity drug would be.

How does Cerebrolysin work?

Mixture of low-molecular-weight neuropeptides claimed to mimic neurotrophic-factor activity (BDNF/GDNF-like effects) and support neuronal survival after ischemia in clinical and preclinical literature.

Is Cerebrolysin FDA approved?

No. Cerebrolysin is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

What is the half-life of Cerebrolysin?

Reported half-life for Cerebrolysin is Mixture; component PK not a single value. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

What peptides are similar to Cerebrolysin?

Compounds most often compared with Cerebrolysin include Semax, N-Acetyl Semax Amidate, Adamax and Selank. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

References

Related research, comparisons & guides

Related peptides

Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 2

This Cerebrolysin profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error

Track Cerebrolysin research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →